Epoetin beta biosimilar (Biocad)

促红素β生物类似药 (Biocad)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEpoetin beta biosimilar (Biocad)

Drug Alias Name依泊汀β生物仿制药 (Biocad)倍他依泊汀生物仿制药 (Biocad)促红素β生物仿制药 (Biocad)

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines

Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists

TargetsErythropoietin receptor

Therapy Area/IndicationsAnemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBIOCAD JSC

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBIOCAD JSC

Active IndicationsN/A

Inactive IndicationsAnemia

ATC CodeN/A